• Isoprinosine in Immunotherapy: Applied Workflows & Troublesh

  2026-05-09

  Isoprinosine (inosine pranobex) offers researchers a dual-action strategy—direct viral inhibition and immune system modulation—with a proven safety profile, making it ideal for translational virology and immunology studies. This guide delivers practical workflows, troubleshooting tips, and experimental insights, bridging the latest mechanistic research with hands-on laboratory applications.

• Nutlin-3a MDM2 Inhibitor: Applied Workflows & Troubleshootin

  2026-05-08

  Nutlin-3a stands out as a best-in-class MDM2 inhibitor, enabling robust p53 pathway activation and apoptosis induction across diverse cancer models. This guide delivers actionable workflows, troubleshooting strategies, and data-driven protocol enhancements, making it essential for translational oncology and advanced mechanistic studies.

• Optimized Niosomal Delivery of Cyclosporine and Pentoxifylli

  2026-05-08

  This study introduces a niosome-based co-delivery system for cyclosporine and pentoxifylline, optimized for effective topical management of psoriasis. Results demonstrate improved drug retention in skin layers and enhanced therapeutic outcomes, highlighting the potential of niosomal formulations to reduce systemic side effects and improve disease management.

• SLU-PP-332 as an ERRα/β/γ Agonist: Mitochondrial and Metabol

  2026-05-07

  The reference study highlights SLU-PP-332 as a potent agonist for estrogen-related receptors ERRα, ERRβ, and ERRγ, revealing its ability to enhance mitochondrial biogenesis, increase energy expenditure, and reduce fat accumulation in preclinical models. These findings position SLU-PP-332 as a promising agent for exercise-mimetic metabolic research and as a potential indirect kidney-protective intervention.

• Translational Impact of CCK-8: Mechanistic Precision in Cell

  2026-05-07

  This article provides translational researchers with a mechanistic and strategic perspective on deploying the Cell Counting Kit-8 (CCK-8) for rigorous cell viability, proliferation, and cytotoxicity assessments. It bridges recent ecotoxicology findings, assay selection strategy, and advanced workflow optimization, contextualizing CCK-8’s value in high-stakes experimental settings. The discussion emphasizes evidence-backed protocol parameters, competitive benchmarking, and real-world translational impact, with a focus on how CCK-8’s water-soluble WST-8 chemistry advances reproducibility and sensitivity—especially in complex, multifactorial exposure studies.

• Isoprinosine and the Evolving Science of Antiviral Immunothe

  2026-05-06

  This thought-leadership article synthesizes mechanistic insights into herpesvirus nuclear egress and immunomodulation, centering on Isoprinosine (inosine pranobex) as both a research tool and translational candidate. Combining evidence from recent discoveries—including the role of CLCC1 in viral membrane fusion—with practical protocol guidance and strategic perspectives, the piece provides actionable intelligence for translational researchers aiming to advance antiviral immunotherapy.

• Pomalidomide (CC-4047): Protocols and Innovations in Myeloma

  2026-05-06

  Pomalidomide (CC-4047) delivers potent immunomodulatory and antineoplastic effects, enabling advanced studies in hematological malignancy research. This guide details experimental protocols, troubleshooting, and key innovations to maximize reliability and reproducibility in multiple myeloma and erythroid cell workflows.

• Isoprinosine: Applied Immunotherapy for Viral Infection Rese

  2026-05-05

  Isoprinosine (inosine pranobex) delivers robust, reproducible immunomodulation and direct antiviral effects, distinguishing it as a tool for researchers tackling viral infections such as HHV-1. This article details actionable workflows, advanced applications, and troubleshooting insights, empowering labs to leverage Isoprinosine for reliable, translatable results.

• Pomalidomide (CC-4047): Advanced Workflows for Myeloma Model

  2026-05-05

  Pomalidomide (CC-4047) transforms hematological malignancy research with its potent immunomodulatory profile and precision in modulating the tumor microenvironment. This guide delivers protocol innovations, troubleshooting tips, and translational insights for maximizing reproducibility in complex multiple myeloma models.

• Cleavage-Resistant TREM2 Enhances Macrophage Efferocytosis i

  2026-05-04

  Dong et al. engineered a synthetic, cleavage-resistant TREM2 (CRT) to bolster macrophage efferocytosis under inflammatory conditions by resisting ADAM17-mediated shedding. Their work demonstrates that in situ delivery of CRT mRNA to macrophages markedly reduces apoptotic cell burden and inflammation in mouse models of steatohepatitis and atherosclerosis, offering a new strategy against chronic inflammatory diseases.

• Competitive STING and CD40 Binding Drives B Cell Activation

  2026-05-04

  This study uncovers how tertiary lymphoid structures (TLS) and their enriched B cell populations contribute to improved prognosis in esophageal squamous cell carcinoma (ESCC). By elucidating the competitive binding of CD40 and STING with TRAF2 and its impact on IRF4-mediated B cell activation, the research provides new mechanistic insight into TLS formation and potential immunotherapeutic targets.

• Ceftolozane/Tazobactam: Advances Against Resistant Gram-Nega

  2026-05-03

  The reference study details the development and clinical profile of ceftolozane/tazobactam, a novel cephalosporin/b-lactamase inhibitor combination with potent activity against multidrug-resistant gram-negative pathogens, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. This review highlights its unique mechanism, pharmacokinetics, and significance in addressing antibiotic resistance, offering critical insights for researchers advancing antimicrobial strategies.

• Pomalidomide (CC-4047): Genomic Insights and Experimental Pr

  2026-05-02

  Explore how Pomalidomide (CC-4047) advances hematological malignancy research by integrating genomic landscape insights with precise experimental design. This article reveals unique evidence-based strategies for leveraging CC-4047 in the evolving era of multiple myeloma study.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ) in Immunotherapy Workflows

  2026-05-01

  EZ Cap™ Mouse IL-12 mRNA (m1Ψ) provides immunology researchers with a stabilized, low-immunogenicity mRNA platform for precision immune activation and translational immunotherapy research. This article details stepwise protocols, advanced use-cases, and troubleshooting strategies for maximizing experimental outcomes with this APExBIO product.

• AT-406 (SM-406): Optimizing Apoptosis Activation in Cancer C

  2026-05-01

  AT-406 (SM-406) unlocks precise, multi-level apoptosis pathway activation in cancer research by targeting IAPs, thereby sensitizing resistant tumor cells and enhancing the efficacy of standard chemotherapeutics. This article details experimental workflows, troubleshooting strategies, and insights that bridge atomic-level mechanism with real-world protocol decisions.

16232 records 1/1083 page Next 12345 下5页 Last page